|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, April 04, 2012 ) Chicago, Illinois - The Stockfather (www.thestockfather.com) believes that Galena Biopharma Inc. (NasdaqCM: Gale) has the pipeline intact to become a fifty dollar stock someday, as of right now (GALE) has so much promise with their NeuVax cancer drug, that Galena Biopharma Inc. (GALE) should be trading somewhere between $5 and $10 as it stands now.
Galena Biopharma has a great looking pipeline, with all of their candidates ready to start the next phases.
To view Galena Biopharma's pipline, click on this link: http://www.galenabiopharma.com/pipeline
The Stockfather rates (GALE) a "buy and hold", with a 6 month target price of $8.00.
Human Genome Sciences Inc. (NasdaqGS: HGSI) has dropped from the $10.50 range, to the $8.00 range over the past two months, but in all actuality should still be trading higher.
Human Genome Sciences Inc. (HGSI) is seeing higher volume over the past week and could see a small jump soon.
Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX) took a beating after they announced that the company's colorectal cancer drug "Perifosine" didn't have the results they wanted in clinical trials.
Keryx Biopharmaceuticals Inc. (KERX) is a bottom bounce candidate and could jump back up to $2.00 in the next couple of weeks.
BioSante Pharmaceuticals, Inc. (NasdaqGM: BPAX) is another biotech that took a dump after their clinical trial didn't produce the results they hope for.
BioSante Pharmaceuticals, Inc. (BPAX) is currently trading at .73 cents, down more than 80% from their 52 week high of $4.02.
AEterna Zentaris Inc. (NasdaqGM: AEZS) took a dive on news that their cancer drug "Perifosine" had unfavorable clinical results.
AEterna Zentaris Inc. (AEZS) collaborated with (KERX) on Perifosine and when (KERX) dove, (AEZS) did as well.
Out of the five pharmaceutical and biotechnology stocks listed, (GALE) has the most promise and should continue to hear news and updates from Galena Biopharma Inc., as their whole pipeline is set to start new phases.
The Stockfather publishes a newsletter to its subscribers at http://www.thestockfather.com.
About The Stockfather:
The Stockfather searches the markets (from OTC to NYSE) for stocks positioned to make big gains. Stocks and companies are featured on The Stockfather web site and e-newsletter.
Disclaimer:
For this news release, The Stockfather was not paid to profile the company(ies) or stock(s) mentioned. The Stockfather does not own any shares of the stock(s) mentioned. The Stockfather is not a registered investment advisor. Investors are responsible for doing their own research and obtaining professional investment advice. Investors should visit http://www.thestockfather.com for further disclosure information.
The Stockfather
David Conway
312-367-5211
alerts@thestockfather.com 
Source: EmailWire.com
|
|
|
|
